Ser909
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser909  -  LATS1 (human)

Site Information
HQRCLAHsLVGTPNY   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 457594
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 3 , 8 , 9 , 10 ) , mass spectrometry ( 6 , 10 , 12 , 14 , 15 , 16 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 26 , 27 , 28 ) , mutation of modification site ( 8 , 10 ) , phospho-antibody ( 3 , 4 , 5 , 7 , 8 , 9 , 10 , 13 , 25 ) , western blotting ( 3 , 4 , 5 , 7 , 8 , 9 , 10 , 13 , 25 )
Disease tissue studied:
breast cancer ( 12 , 13 ) , HER2 positive breast cancer ( 6 ) , luminal A breast cancer ( 6 ) , luminal B breast cancer ( 6 ) , breast cancer, triple negative ( 6 , 12 ) , liver cancer ( 3 ) , hepatocellular carcinoma ( 3 ) , lung cancer ( 14 , 15 , 16 , 18 , 20 ) , non-small cell lung cancer ( 14 , 16 , 18 , 19 , 20 ) , non-small cell lung adenocarcinoma ( 14 , 15 , 16 , 18 ) , non-small cell large cell lung carcinoma ( 14 , 16 ) , non-small cell squamous cell lung carcinoma ( 15 ) , ovarian cancer ( 4 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 4 ) , 293A (epithelial) ( 9 , 10 ) , 293T (epithelial) ( 5 ) , A549 (pulmonary) ( 19 ) , breast ( 6 , 12 ) , Cal-12T (pulmonary) ( 18 ) , Calu 6 (pulmonary) ( 20 ) , E.coli (bacterial) ( 8 ) , HCC15 (pulmonary) ( 15 ) , HCC44 (pulmonary) ( 18 ) , HCC78 (pulmonary) ( 16 ) , HeLa (cervical) ( 13 ) , Hep3B (hepatic) ( 3 ) , Huh7 (hepatic) ( 3 ) , Jurkat (T lymphocyte) ( 21 , 22 , 26 , 27 , 28 ) , LOU-NH91 (squamous) ( 15 ) , lung ( 14 , 15 , 16 , 18 ) , MCF-7 (breast cell) ( 13 ) , MCF10A1 (epithelial) ( 25 ) , MDA-MB-231 (breast cell) ( 13 ) , NCI-H1299 (pulmonary) ( 14 ) , NCI-H1437 (pulmonary) ( 18 ) , NCI-H1648 (pulmonary) ( 20 ) , NCI-H1666 (pulmonary) ( 18 ) , NCI-H1703 (squamous) ( 15 ) , NCI-H1734 (pulmonary) ( 14 ) , NCI-H1781 (pulmonary) ( 16 ) , NCI-H1944 (pulmonary) ( 14 ) , NCI-H2073 (pulmonary) ( 15 ) , NCI-H2228 (pulmonary) ( 16 ) , NCI-H2342 (pulmonary) ( 15 ) , NCI-H2405 (pulmonary) ( 18 ) , NCI-H3122 (pulmonary) ( 16 ) , NCI-H358 (pulmonary) ( 14 ) , NCI-H460 (pulmonary) ( 14 ) , NCI-H661 (pulmonary) ( 16 ) , PLC/PRF/5 (hepatic) ( 3 ) , SKOV-3 (ovarian) ( 4 )

Upstream Regulation
Regulatory protein:
COL4A1 (human) ( 3 ) , FRMD6 (human) ( 25 )
Kinases, in vitro:
LATS1 (human) ( 8 ) , MST2 (human) ( 30 )
Treatments:
2-deoxyglucose ( 10 ) , CNO ( 4 ) , FGF2 ( 7 ) , glomerular antiserum ( 5 ) , PD98059 ( 13 ) , U0126 ( 13 ) , virus infection ( 9 ) , Y15 ( 3 )

Downstream Regulation
Effects of modification on LATS1:
enzymatic activity, induced ( 30 )

References 

1

Frank SR, et al. (2018) p190 RhoGAP promotes contact inhibition in epithelial cells by repressing YAP activity. J Cell Biol
29934311   Curated Info

2

Mei L, et al. (2017) SUMOylation of large tumor suppressor 1 at Lys751 attenuates its kinase activity and tumor-suppressor functions. Cancer Lett 386, 1-11
27847303   Curated Info

3

Wong KF, et al. (2016) Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma. Oncotarget 7, 77683-77695
27765911   Curated Info

4

Yagi H, et al. (2016) GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer. Oncogene 35, 4471-80
26804165   Curated Info

5

Keyvani Chahi A, Martin CE, Jones N (2016) Nephrin Suppresses Hippo Signaling through the Adaptor Proteins Nck and WTIP. J Biol Chem 291, 12799-808
27033705   Curated Info

6

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

7

Hua G, et al. (2016) YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells. Oncogene 35, 2247-65
26364602   Curated Info

8

Ni L, et al. (2015) Structural basis for Mob1-dependent activation of the core Mst-Lats kinase cascade in Hippo signaling. Genes Dev 29, 1416-31
26108669   Curated Info

9

Liu G, et al. (2015) Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway. Oncogene 34, 3536-46
25195862   Curated Info

10

Mo JS, et al. (2015) Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nat Cell Biol 17, 500-10
25751140   Curated Info

11

DeRan M, et al. (2014) Energy Stress Regulates Hippo-YAP Signaling Involving AMPK-Mediated Regulation of Angiomotin-like 1 Protein. Cell Rep 9, 495-503
25373897   Curated Info

12

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

13

Yang S, et al. (2014) Phosphorylation of KIBRA by the extracellular signal-regulated kinase (ERK)-ribosomal S6 kinase (RSK) cascade modulates cell proliferation and migration. Cell Signal 26, 343-51
24269383   Curated Info

14

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

15

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

16

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

17

Adler JJ, et al. (2013) Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases. Proc Natl Acad Sci U S A 110, 17368-73
24101513   Curated Info

18

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

19

Rikova K (2012) CST Curation Set: 16144; Year: 2012; Biosample/Treatment: cell line, A549/iressa, gleevec, crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]
Curated Info

20

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

21

Guo A (2012) CST Curation Set: 13981; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

22

Mulhern D (2012) CST Curation Set: 13109; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

23

Rikova K (2012) CST Curation Set: 13732; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 1/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

24

Rikova K (2012) CST Curation Set: 13734; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 3/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

25

Angus L, et al. (2012) Willin/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP. Oncogene 31, 238-50
21666719   Curated Info

26

Mulhern D (2011) CST Curation Set: 13110; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -;
Curated Info

27

Guo A (2011) CST Curation Set: 11886; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

28

Guo A (2011) CST Curation Set: 11890; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

29

Praskova M, Xia F, Avruch J (2008) MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell proliferation. Curr Biol 18, 311-21
18328708   Curated Info

30

Chan EH, et al. (2005) The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene 24, 2076-86
15688006   Curated Info